REFERENCES

1. Gault J, Sain S, Hu LJ, Awad IA. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery 2006;59:1278-84; discussion 1284-5.

2. Shenkar R, Shi C, Rebeiz T, et al. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med 2015;17:188-96.

3. Tang AT, Sullivan KR, Hong CC, et al. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med 2019;11:eaaw3521.

4. Gunel M, Awad IA, Finberg K, et al. A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. N Engl J Med 1996;334:946-51.

5. Liquori CL, Berg MJ, Squitieri F, et al. Deletions in CCM2 are a common cause of cerebral cavernous malformations. Am J Hum Genet 2007;80:69-75.

6. U.S. Food & Drug Administration. Enhancing the diversity of clinical trial populations - eligibility criteria, enrollment practices, and trial designs guidance for industry, November 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial [Last accessed on 2 Nov 2021].